Barbarossa Alexia, Rosato Antonio, Carrieri Antonio, Fumarola Luciana, Tardugno Roberta, Corbo Filomena, Fracchiolla Giuseppe, Carocci Alessia
Department of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.
Interdisciplinary Department of Medicine, School of Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.
Pharmaceuticals (Basel). 2024 Aug 23;17(9):1109. doi: 10.3390/ph17091109.
The emergence and spread of drug-resistant pathogens, resulting in antimicrobial resistance, continue to compromise our capability to handle commonly occurring infectious diseases. The rapid global spread of multi-drug-resistant pathogens, particularly systemic fungal infections, presents a significant concern, as existing antimicrobial drugs are becoming ineffective against them. In recent decades, there has been a notable increase in systemic fungal infections, primarily caused by species, which are progressively developing resistance to azoles. Moreover, species biofilms are among the most common in clinical settings. In particular, they adhere to biomedical devices, growing as a resilient biofilm capable of withstanding extraordinarily high antifungal concentrations. In recent years, many research programs have concentrated on the development of novel compounds with possible antimicrobial effects to address this issue, and new sources, such as plant-derived antimicrobial compounds, have been thoroughly investigated. Essential oils (EOs), among their numerous pharmacological properties, exhibit antifungal, antibacterial, and antiviral activities and have been examined at a global scale as the possible origin of novel antimicrobial compounds. A recent work carried out by our research group concerned the synergistic antibacterial activities of commercially available and chemically characterized L. essential oil ( EO) in association with sertraline, a selective serotonin reuptake inhibitor whose repositioning as a non-antibiotic drug has been explored over the years with encouraging results. The aim of this work was to explore the synergistic effects of EO with sertraline on both planktonic and sessile species cells. Susceptibility testing and testing of the synergism of sertraline and EO against planktonic and sessile cells were performed using a broth microdilution assay and checkerboard methods. A synergistic effect was evident in both the planktonic cells and mature biofilms, with significant reductions in fungal viability. Indeed, the fractional inhibitory concentration index (FICI) was lower than 0.5 for all the associations, thus indicating significant synergism of the associations with the strains examined. Moreover, the concentrations of sertraline able to inhibit Candida spp. strain growth and biofilm formation significantly decreased when it was used in combination with EO for all the strains considered, with a reduction percentage in the amount of each associated component ranging from 87.5% to 97%.
耐药病原体的出现和传播导致了抗菌药物耐药性,这继续削弱我们应对常见传染病的能力。多重耐药病原体在全球迅速传播,尤其是系统性真菌感染,这令人深感担忧,因为现有的抗菌药物对它们正逐渐失效。近几十年来,系统性真菌感染显著增加,主要由某些物种引起,这些物种对唑类药物的耐药性正在逐步增强。此外,某些物种的生物膜是临床环境中最常见的生物膜之一。特别是,它们附着在生物医学设备上,形成一种具有弹性的生物膜,能够耐受极高的抗真菌浓度。近年来,许多研究项目都集中在开发具有潜在抗菌作用的新型化合物以解决这一问题,并且对新的来源,如植物源抗菌化合物,进行了深入研究。香精油(EOs)在其众多药理特性中,表现出抗真菌、抗菌和抗病毒活性,并已在全球范围内作为新型抗菌化合物的可能来源进行了研究。我们研究小组最近开展的一项工作涉及市售且经过化学表征的某种罗勒属植物香精油(EO)与舍曲林的协同抗菌活性,舍曲林是一种选择性5-羟色胺再摄取抑制剂,多年来人们一直在探索将其重新定位为非抗生素药物,结果令人鼓舞。这项工作的目的是探索EO与舍曲林对浮游和固着的某些物种细胞的协同作用。使用肉汤微量稀释法和棋盘法对舍曲林和EO对浮游和固着细胞的敏感性及协同作用进行了测试。在浮游细胞和成熟生物膜中均明显存在协同作用,真菌活力显著降低。事实上,所有组合的部分抑菌浓度指数(FICI)均低于0.5,因此表明这些组合与所检测的某些菌株具有显著的协同作用。此外,对于所有考虑的菌株,当舍曲林与EO联合使用时,能够抑制念珠菌属菌株生长和生物膜形成的舍曲林浓度显著降低,每种相关成分的用量减少百分比在87.5%至97%之间。